CISEN(SH:603367)2025-04-21 11:05Financial Performance - The company's operating revenue for 2024 was CNY 3,981,572,232.95, a decrease of 10.77% compared to CNY 4,462,348,636.07 in 2023 [24]. - The net profit attributable to shareholders for 2024 was CNY 508,906,193.71, down 2.38% from CNY 521,338,330.89 in 2023 [24]. - The total profit for 2024 was 576 million RMB, down 3.37% year-on-year [35]. - The net profit attributable to the parent company was 509 million RMB, a decrease of 2.38% compared to the previous year [35]. - The net profit after deducting non-recurring gains and losses was 426 million RMB, down 5.63% year-on-year [35]. - The company's cash flow from operating activities increased by 26.51% to CNY 570,848,680.25 in 2024, compared to CNY 451,240,761.60 in 2023 [24]. - The basic earnings per share for 2024 was CNY 1.12, a decrease of 2.61% from CNY 1.15 in 2023 [26]. - The weighted average return on equity for 2024 was 8.66%, down from 9.49% in 2023, a decrease of 0.83 percentage points [26]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 0.44 per share (including tax) for the fiscal year 2024, with a total distribution amount of RMB 199,211,816.76, accounting for 39.15% of the net profit attributable to shareholders [6]. - As of December 31, 2024, the total share capital of the company is 452,754,129 shares, with a cash dividend of RMB 0.22 per share already distributed in the first half of 2024 [6]. - The company executed two cash dividend distributions in 2024, totaling approximately 197.41 million yuan and 99.61 million yuan, representing 37.87% and 36.85% of the net profit attributable to shareholders, respectively [158][159]. Governance and Compliance - The company has received a standard unqualified audit report from Da Xin Certified Public Accountants, ensuring the accuracy and completeness of the financial report [5]. - The board of directors and supervisory board members have all attended the board meeting, ensuring governance compliance [4]. - The company has not violated decision-making procedures in providing guarantees to external parties [8]. - The company has not faced any issues that would prevent more than half of the directors from guaranteeing the authenticity and completeness of the annual report [8]. - The company maintains a robust governance structure, ensuring compliance with legal regulations and promoting transparency in information disclosure [121]. Research and Development - The company has over 100 ongoing research projects focusing on complex injection preparations, controlled-release oral solid preparations, and other therapeutic areas [38]. - R&D investment accounts for over 8% of the company's revenue, supporting its transformation and sustainable development [56]. - The company invested CNY 343 million in R&D for 2024, with over 100 projects in progress focusing on complex injections, controlled-release oral solid preparations, and other therapeutic areas [86]. - The company is focusing on innovative drugs targeting diseases with unmet treatment needs, with several new drugs in various clinical trial phases [87]. - The company is actively pursuing collaborations for R&D projects under the MAH policy, aiming to expand its product offerings [85]. Market and Product Development - The company is enhancing its marketing strategy by optimizing human resources and performance incentives to improve overall marketing effectiveness [36]. - The company has introduced new products, including Bromfenac Sodium Eye Drops and Dexmedetomidine Hydrochloride Injection, expanding its product portfolio [78]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on complementary businesses [79]. - The company is focusing on expanding its product portfolio in the therapeutic areas of neurology and immunology, with multiple products in various stages of clinical research [92]. Environmental Responsibility - The company has implemented various pollution prevention measures, including the installation of activated carbon treatment equipment for waste gas emissions [178]. - The company has received multiple environmental impact assessments and approvals for its production projects from the Jining Environmental Protection Bureau [179]. - The company reported a total wastewater discharge of 58,642 m³ for the year [186]. - The actual concentration of chemical oxygen demand (COD) in wastewater was 72 mg/L, significantly below the limit of 500 mg/L [186]. - The company has not faced any administrative penalties related to environmental issues during the reporting period [184]. Strategic Outlook - The company provided a future outlook with a revenue guidance of 1,875.1 million for the next quarter, indicating a projected growth rate of 10% [131]. - The company is focusing on optimizing supply chain management and enhancing production efficiency to cope with the pressures of centralized procurement and price competition [111]. - The company is committed to enhancing high-end drug supply capabilities and accelerate the development of innovative drugs and first-generic drugs, as outlined in the "Pharmaceutical Industry High-Quality Development Action Plan (2023-2025)" [111]. - The company is exploring international market expansion, aiming for a year-on-year increase in formulation export scale [114].